DRUG
GLP-1 Receptor Agonists
Participants receive GLP-1 RA or GLP-1/GIP dual agonists as part of their standard care for overweight or obesity
Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases
Status
Recruiting
Phase
Not applicable
Enrollment
100
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or drivers of sarcopenia / sarcopenic obesity in this population. .
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Jul 14, 2026
Study start
Feb 19, 2026
Primary completion
Dec 31, 2056
Study completion
Dec 31, 2056
Results posted
Not reported
Registry updated
Jul 14, 2026
Outcomes
What the study measures.
Primary outcomes
Prevalence of sarcopenia / sarcopenic obesity
Time frame · From February 2026 to december 2056
Secondary outcomes
Myokines levels in serum or plasma
Time frame · February 2026 to December 2056
Myokines levels in serum or plasma as measured by ELISA
Myokine expression
Time frame · February 2026 to December 2056
Myokine expression in muscle as measured by RT-qPCR or RNA-Seq
Prevalence of MASLD
Time frame · March 2026 to December 2056
MASLD as evaluated by Fibroscan, based on controlled attenuation parameter (CAP, in decibels per meter) as a marker of hepatic steatosis
Prevalence of MASH
Time frame · March 2026 to December 2056
Prevalence of MASH as evaluated by Fibroscan, based on Liver stiffness measurement (LSM, in kilopascals) as a surrogate of liver fibrosis
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Metabolic or endocrine disease Exclusion Criteria: * Known myopathy * Systemic steroid use (\> 1 mg/kg hydrocortisone) or exogenous Cushing's syndrome * Psychological, family, sociological or geographical conditions that could potentially limit compliance with the study protocol * History of cancer within the five years prior to the study or Cushing's syndrome due to ACTH-secreting tumor
Study locations
1 registered sites.
Belgium. Showing up to 24 locations stored in the fast local snapshot.
Cliniques Universitaires Saint-Luc
Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, Belgium
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Glucagon.
NCT IDStudyPhase / statusEnrollmentUpdated
Fibrosis Lessens After Metabolic Surgery
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity
Shahid Beheshti University of Medical Sciences · Heart Failure and Reduced Ejection Fraction · Obesity & Overweight
Phase 3
Not yet recruiting
60
2026-07
Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion
Alaa Sada · Mild Autonomous Cortisol Secretion (MACS) · Adrenalectomy; Status
Phase 2
Recruiting
34
2026-07
Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.
China-Japan Friendship Hospital · Obesity
Not applicable
Recruiting
400
2026-07
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial
yifang zhu · Acute Ischemic Stroke (AIS)
Phase 2 / Phase 3
Not yet recruiting
430
2026-07
Tirzepatide for Treatment of CCCA
Johns Hopkins University · Central Centrifugal Cicatricial Alopecia (CCCA)
Phase 2
Not yet recruiting
20
2026-07
GLP-1R Agonist Treatment for Opioid Use Disorder
Milton S. Hershey Medical Center · Opioid Use Disorder · Opioid Abuse and Addiction
Phase 2
Recruiting
200
2026-07
Tirzepatide in Idiopathic Intracranial Hypertension Trial
Duke University · Idiopathic Intracranial Hypertension (IIH)
Phase 4
Not yet recruiting
60
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.